Shereen Rafee

500 total citations
15 papers, 328 citations indexed

About

Shereen Rafee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Shereen Rafee has authored 15 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Shereen Rafee's work include Lung Cancer Treatments and Mutations (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Cancer Genomics and Diagnostics (3 papers). Shereen Rafee is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Cancer Genomics and Diagnostics (3 papers). Shereen Rafee collaborates with scholars based in Ireland, Australia and United Kingdom. Shereen Rafee's co-authors include Kenneth J. O’Byrne, Yasir Y. Elamin, Kathy Gately, Sinéad Cuffe, Stephen P. Finn, Bryan T. Hennessy, Sinéad Toomey, Raffaele Califano, Georgios Tsakonas and Christoph Ackermann and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Shereen Rafee

15 papers receiving 327 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shereen Rafee Ireland	8	161	148	76	43	41	15	328
Roberto Borea Italy	7	169 1.0×	186 1.3×	82 1.1×	26 0.6×	47 1.1×	25	363
Daniela Bianconi Austria	10	100 0.6×	161 1.1×	64 0.8×	51 1.2×	74 1.8×	23	306
Jennifer D. Morrissette United States	7	156 1.0×	88 0.6×	39 0.5×	29 0.7×	57 1.4×	11	311
Hiu Fung Yuen Singapore	8	256 1.6×	123 0.8×	52 0.7×	21 0.5×	86 2.1×	9	350
Chiho Nakashima Japan	10	99 0.6×	140 0.9×	107 1.4×	23 0.5×	77 1.9×	24	278
John Joseph Wright United States	8	72 0.4×	141 1.0×	81 1.1×	80 1.9×	29 0.7×	31	312
Hiroyuki Goda Japan	13	206 1.3×	146 1.0×	45 0.6×	61 1.4×	81 2.0×	30	381
Tomohisa Okuno Japan	11	216 1.3×	122 0.8×	74 1.0×	46 1.1×	143 3.5×	27	377
Anna Shvartsur United States	5	124 0.8×	194 1.3×	65 0.9×	35 0.8×	33 0.8×	6	317
Arsène‐Bienvenu Loembé United Kingdom	9	168 1.0×	196 1.3×	100 1.3×	19 0.4×	33 0.8×	15	377

Countries citing papers authored by Shereen Rafee

Since Specialization

Citations

This map shows the geographic impact of Shereen Rafee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shereen Rafee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shereen Rafee more than expected).

Fields of papers citing papers by Shereen Rafee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shereen Rafee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shereen Rafee. The network helps show where Shereen Rafee may publish in the future.

Co-authorship network of co-authors of Shereen Rafee

This figure shows the co-authorship network connecting the top 25 collaborators of Shereen Rafee. A scholar is included among the top collaborators of Shereen Rafee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shereen Rafee. Shereen Rafee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Lindsay, Colin R., Pantelis Nicola, Andreas Gruber, et al.. (2023). Abstract 6463: Persistence of smoking mutational signatures in the non-small cell lung cancer genome. Cancer Research. 83(7_Supplement). 6463–6463. 1 indexed citations

Elamin, Yasir Y., Kathy Gately, Shereen Rafee, et al.. (2023). Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences. 24(13). 10545–10545. 7 indexed citations

Rafee, Shereen, et al.. (2022). ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer. Oncology and Therapy. 10(1). 13–22. 3 indexed citations

Osborne, Lucy R., Clare Hodgson, Mark S. Pearce, et al.. (2022). Real-world use of different pembrolizumab regimens (3 weekly versus 6 weekly) in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 165. S46–S46. 1 indexed citations

Farrelly, Angela M., Mattia Cremona, Paul A. Armstrong, et al.. (2021). Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. Journal of Translational Medicine. 19(1). 184–184. 28 indexed citations

Nicola, Pantelis, Shereen Rafee, George J. Burghel, et al.. (2020). Abstract 3810: Persistence of smoking signature 4 in the non-small cell lung cancer genome. Cancer Research. 80(16_Supplement). 3810–3810. 1 indexed citations

Califano, Raffaele, Fábio Gomes, Christoph Ackermann, et al.. (2019). Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations?. European Journal of Cancer. 125. 1–11. 29 indexed citations

Teo, Min Yuen, Sinéad Toomey, Shereen Rafee, et al.. (2017). Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). 11587–11587. 1 indexed citations

Finn, Stephen P., et al.. (2016). Targeting the fibroblast growth factor receptor family in cancer. Cancer Treatment Reviews. 46. 51–62. 98 indexed citations

10.

Rafee, Shereen, Yasir Y. Elamin, Mary Toner, et al.. (2015). Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement. Faculty of Health; Institute of Health and Biomedical Innovation. 2 indexed citations

11.

Elamin, Yasir Y., et al.. (2015). Thymidine Phosphorylase in Cancer; Enemy or Friend?. Cancer Microenvironment. 9(1). 33–43. 76 indexed citations

12.

Rafee, Shereen, Yasir Y. Elamin, Mary Toner, et al.. (2015). Neoadjuvant Crizotinib in Advanced Inflammatory Myofibroblastic Tumour with ALK Gene Rearrangement. Tumori Journal. 101(2). e35–e39. 14 indexed citations

13.

Elamin, Yasir Y., Shereen Rafee, Sinéad Toomey, & Bryan T. Hennessy. (2014). Immune Effects of Bevacizumab: Killing Two Birds with One Stone. Cancer Microenvironment. 8(1). 15–21. 44 indexed citations

14.

Rafee, Shereen, et al.. (2014). A rare case of nasopharyngeal carcinoma with widespread CNS metastases.. PubMed. 107(6). 180–1. 5 indexed citations

15.

Elamin, Yasir Y., Shereen Rafee, Cathal Ó’Brien, et al.. (2013). Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience. European Archives of Oto-Rhino-Laryngology. 271(8). 2253–2259. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact